Compare Hilton Hotels Corporation Common Stock (HLT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Summit Therapeutics Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $324.2 (market cap $73.63B), while Summit Therapeutics Inc trades at $14.44 (market cap $10.48B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 7× Summit Therapeutics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HLT | SMMT | |
|---|---|---|
Market Cap | $73.63B | $10.48B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $29.32 |
52-Week Low | $256.75 | $13.05 |
Enterprise Value | $86.12B | $9.90B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.22, up 0.59% with a bearish technical signal despite consistent earnings beats. The company shows strong fundamentals with 2025 revenue of $12.04B and net income of $1.46B, though valuation metrics appear elevated with a P/E of 49.06. Recent developments include brand expansion initiatives and upcoming Q2 2026 earnings on July 28, 2026.
Wall Street maintains a bullish outlook with 55% buy ratings and a $345.18 price target, representing 6.8% upside. Key risks include rising debt levels (debt-to-asset ratio increased to 73.88% in 2025) and technical weakness. The stock offers growth potential through Hilton's brand expansion but faces headwinds from high valuation and negative shareholder equity.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
